Aqr Capital Management LLC Glycomimetics Inc Transaction History

Aqr Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$1.8 - $2.39 $175,662 - $233,240	-97,590 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$2.16 - $3.18 $247,315 - $364,103	-114,498 Reduced 53.99%	97,590 $226,000
Q1 2021 May 17, 2021	BUY	$2.89 - $4.22 $612,934 - $895,011	212,088 New	212,088 $638,000
Q4 2020 Feb 16, 2021	SELL	$2.69 - $4.24 $131,766 - $207,692	-48,984 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.07 - $5.0 $1,977 - $3,220	644 Added 1.33%	48,984 $150,000
Q2 2020 Aug 17, 2020	SELL	$2.06 - $3.76 $12,621 - $23,037	-6,127 Reduced 11.25%	48,340 $182,000
Q1 2020 May 15, 2020	BUY	$1.83 - $5.41 $65,091 - $192,428	35,569 Added 188.22%	54,467 $124,000
Q4 2019 Feb 14, 2020	BUY	$4.03 - $6.5 $76,158 - $122,837	18,898 New	18,898 $100,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.